Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL

This study has been completed.
Sponsor:
Information provided by:
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT00236080
First received: October 7, 2005
Last updated: July 12, 2013
Last verified: July 2013

October 7, 2005
July 12, 2013
August 2005
Not Provided
  • Multiple Sleep Latency Test (MSLT) [ Time Frame: Endpoint (Visit 4) change from baseline (Visit 2) ] [ Designated as safety issue: No ]
    The Multiple Sleep Latency Test (MSLT) is an objective assessment of sleepiness that measures the likelihood of falling asleep. Five 20-minute (maximum) MSLT naps were performed (at 2300, 0100, 0300, 0500, and 0700) at both the screening/baseline assessment visit (Visit 2) and at endpoint (Visit 4). Each nap was terminated after 20 minutes if no sleep occurred. Sleep latency was measured as the elapsed time from lights out to the first epoch scored as sleep.
  • Psychomotor Vigilance Task (PVT) [ Time Frame: Endpoint (Visit 4) change from baseline (Visit 2) ] [ Designated as safety issue: No ]
    The computer-based PVT took 10 minutes to complete and measured reaction time stimulus in milliseconds. The reaction time consisted of the digits 000 initially appearing in a window on the PVT device, after which the 3-digit numbers increased in milliseconds until the response button was pressed by the patient. The resulting number at the button press was the reaction time in milliseconds. There was a variable 1- to 10-second interstimulus interval. After pressing the button in response to each stimulus, the button was released and the patient awaited the next stimulus.
  • The purpose of the study is to compare the overnight efficacy and plasma
  • concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in
  • patients with excessive sleepiness associated with chronic SWSD.
Complete list of historical versions of study NCT00236080 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil (150, 200, and 250 mg) and PROVIGIL® (200 mg) in Patients With Chronic Shift Work Sleep Disorder

The purpose of the study is to compare the overnight efficacy and plasma concentration-time profiles of armodafinil and PROVIGIL, after multiple doses, in patients with excessive sleepiness associated with chronic Shift Work Sleep Disorder (SWSD).

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL in Patients with Chronic Shift Work Sleep Disorder

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Chronic Shift Work Sleep Disorder
  • Drug: PROVIGIL 200 mg
    PROVIGIL 200 mg/day
  • Drug: Armodafinil 250 mg
    Armodafinil 250 mg/day
  • Drug: Armodafinil 200 mg
    Armodafinil 200 mg/day
  • Drug: Armodafinil 150 mg
    Armodafinil 150 mg/day
  • Drug: Placebo
    Matching placebo tablets
  • Experimental: 1
    PROVIGIL 200 mg/day
    Intervention: Drug: PROVIGIL 200 mg
  • Experimental: 2
    Armodafinil 250 mg/day
    Intervention: Drug: Armodafinil 250 mg
  • Experimental: 3
    Armodafinil 200 mg/day
    Intervention: Drug: Armodafinil 200 mg
  • Experimental: 4
    Armodafinil 150 mg/day
    Intervention: Drug: Armodafinil 150 mg
  • Placebo Comparator: 5
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
136
December 2005
Not Provided

Inclusion Criteria:

Patients are included in the study if all of the following criteria are met:

  • The patient speaks and writes in English.
  • The patient is a man or woman of any ethnic origin aged 18 through 65 years.
  • The patient is in good health as determined by a medical and psychiatric history, medical examination, serum chemistry, and hematology.
  • The patient has a diagnosis of SWSD according to the International Classification of Sleep Disorders (ICSD) criteria, and must have had excessive sleepiness during night shifts for at least 3 months.
  • The patient must be planning to work at least 3 to 5 nights (per week), of which at least 3 nights will be consecutive.
  • The patient must work night shifts that include at least 6 hours between 2200 and 0800 (+30 minutes) and be no longer than 12 hours (+30 minutes) in duration.
  • The patient has a mean sleep latency of 6 minutes or less as determined by the MSLT (average of naps at 0100, 0300, 0500, and 0700).
  • The patient has a Clinical Global Impression of Severity of Illness (CGI-S) rating of 4 or more as it pertains to sleepiness during night shifts including the commute from work.
  • Women of childbearing potential (not surgically sterile or 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. Acceptable methods of contraception include abstinence, barrier method with spermicide, steroidal contraceptive (oral, transdermal, implanted and injected) in conjunction with a barrier method, and intrauterine device (IUD).
  • The patient is willing to comply with study restrictions and remain at the clinic overnight as required.
  • The patient may have been prescribed PROVIGIL or stimulant therapy for their sleep disorder; however, they must have undergone a washout period of at least 7 days prior to screening assessments done at the second screening visit.

Exclusion Criteria:

Patients are excluded from participating in this study if 1 or more of the following criteria are met:

  • The patient has any clinically significant medical or psychiatric conditions (treated or untreated).
  • The patient has a probable diagnosis of a current sleep disorder other than SWSD.
  • The patient consumes caffeine including coffee, tea, and/or other caffeine-containing beverages or foods averaging more than 600 mg of caffeine/day within 2 weeks of the start of study drug administration.
  • The patient has medically unexplainable positive urine drug screen (UDS) result at the screening visit.
  • The patient has clinically significant deviation from normal in clinical laboratory results, vital signs, or physical examination.
  • The patient has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before study drug administration, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before study drug adminstration.
  • The patient used any prescription drugs disallowed by the protocol or clinical significant use of over-the-counter (OTC) drugs within 7 days before the second screening/baseline visit.
  • The patient has any disorder (including gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion.
  • The patient has known or suspected hypersensitivity to stimulants and/or modafinil or any ingredient present in the study drug.
  • The patient has a history (within the past 5 years) of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual or Mental Disorders of the American Psychiatric Association, Fourth Edition, Text Revision (DSM-IV-TR).
  • The patient is a pregnant or lactating woman.
  • The patient has donated, within 56 days prior to study drug administration, any blood or plasma in excess of 450 mL.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00236080
C10953/3045/CM/US
Not Provided
Sponsor's Medical Expert, Cephalon
Cephalon
Not Provided
Study Director: Gwendolyn Neibler, DO Cephalon
Teva Pharmaceutical Industries
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP